|Articles|July 1, 2004

Combo yields results

Maxim Pharmaceuticals has announced that advanced metastatic melanoma patients treated with a combination of Ceplene and Interleukin-2 (IL-2) showed improved survival rates in a phase 3 trial, according to a Business Wire report.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME